Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

What Was Tested

Researchers studied Teriparatide in this randomized controlled trial publication.

The effects of teriparatide versus alendronate were compared by gender and menopausal status in patients with glucocorticoid-induced osteoporosis.

The researchers examined effects of teriparatide versus alendronate by gender and menopausal status.

Who Took Part

The study group was 277 women.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and multicenter study.

The women were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

As a double-blind Teriparatide study, the assignments were hidden from both participants and investigators until the end.

More than one site took part, so the women came from several places.

Primary outcome was change in lumbar spine BMD.

Secondary outcomes included change in hip BMD, change in bone biomarkers, fracture incidence, and safety.

What Was Measured

Topics PubMed links to this paper include Age Factors, Alendronate, Bone Density, Bone Density Conservation Agents, Glucocorticoids, Hip Joint and Lumbar Vertebrae.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Teriparatide in 277 women.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.